What is a 'failure' of bisphosphonate therapy for osteoporosis?
John J. Carey, MD
Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation
Address: John J. Carey, MD, Department of Rheumatic and Immunologic Diseases, A50, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail email@example.com
Dr. Carey has indicated that he has received grant or research support from the Proctor and Gamble corporation, serves as a consultant for Eli Lilly and Company, and is on the speaker’s bureau of Proctor and Gamble.
ABSTRACTAssessing the effectiveness of bisphosphonate therapy is problematic. Bone mineral density and markers of bone turnover are often used, but the true measure is prevention of new fractures.